Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,010 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06476093Recruiting
Radiation plus anlotinib for lung cancer brain spread
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Lianyungang, JiangsuAges 18–80 - NCT07820423Recruiting
AI tool predicts high-risk lung cancer linked to air-filled spaces
This study uses artificial intelligence to examine CT scans and predict whether lung cancer containing air-filled spaces is aggressive. It may help doctors tailor treatment after surgery.
Changsha, HunanAges 18 years+ - NCT07807696Recruiting
Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax
This study tests whether drinking olive oil before lung cancer surgery reduces the risk of chylothorax, a condition where lymph fluid builds up in the chest.
Shanghai, XuhuiAges 18–80 - NCT05654454RecruitingPhase 3
Bevacizumab plus chemotherapy vs Avastin for advanced lung cancer
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
ArkhangelskAges 18 years+ - NCT07716527Enrolling by invitation
Testing a web tool for lung cancer screening
This study is testing a new website-based tool to help people decide if they should get screened for lung cancer. You may be eligible if you are between 50 and 80 years old and currently smoke or recently quit.
New Brunswick, New JerseyAges 50–80 - NCT07669779RecruitingPhase 2
Study of AK146D1 and AK112 for advanced lung cancer
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07631624Recruiting
Blood test for lung cancer screening in smokers and former smokers
This study tests whether a simple blood test that detects smoking-related changes in DNA can help identify who should get lung cancer screening. Researchers want to see if this test is better at finding people at risk than current methods.
Antwerp, AntwerpenAges 50 years+ - NCT07623356RecruitingPhase 1/Phase 2
Study of AK138D1 alone or with ivonescimab for advanced lung cancer
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06706713RecruitingPhase 2
Testing BEBT-109 for advanced EGFR exon 20 lung cancer
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06734182RecruitingPhase 2
Targeted therapy plus chemo before surgery for HER2-mutant lung cancer
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
GuangzhouAges 18–75 - NCT07538804RecruitingPhase 1/Phase 2
Testing ANS02 for EGFR-Mutated Lung Cancer
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
Fairfax, VirginiaAges 18 years+ - NCT07489716RecruitingPhase 2
Study of SHR-1826 for advanced non-small cell lung cancer
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
Jinan, ShandongAges 18–75 - NCT06775821Recruiting
Lung cancer and abdominal aneurysm screening study
This study looks at how common abdominal aortic aneurysms (bulges in the belly's main artery) are in people with primary lung cancer. It involves a simple imaging test to check for this condition.
Kunming, YunnanAges 20–90 - NCT07473128RecruitingPhase 3
Trilaciclib to prevent low blood cell counts in limited-stage small cell lung cancer
This trial tests whether taking trilaciclib alongside standard chemotherapy can help prevent low blood cell counts (myelosuppression) in people with limited-stage small cell lung cancer. It may help you stay stronger during treatment.
Oakland, CaliforniaAges 18 years+ - NCT07463300Recruiting
AI Study for Lung Cancer Type and Genetics via PET/CT
This study uses an AI system that looks at your PET/CT scan images to figure out the exact type and genetic makeup of your non-small cell lung cancer. The goal is to improve how doctors classify and treat your cancer without needing extra invasive tests.
Guangzhou, GuangdongAges 18 years+ - NCT07444437RecruitingPhase 2
LM103 after surgery for lung cancer
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
Guangzhou, GuangdongAges 18–75 - NCT07433283RecruitingPhase 1/Phase 2
Iron nanoparticle injection for advanced solid tumors
This trial tests a new treatment for advanced solid tumors that uses tiny iron particles guided by carbon nanoparticles, injected directly into the tumor. It may be an option if standard treatments have stopped working or aren't available, and you have a tumor that can be safely injected.
Beijing, Beijing MunicipalityAges 18–80 - NCT07416994RecruitingPhase 3
Study of YL202 vs. docetaxel for advanced EGFR-mutant lung cancer
This trial tests a new drug, YL202, against a standard chemotherapy (docetaxel) for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if YL202 works better for those whose cancer has progressed after prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07423169Recruiting
Partial tumor radiation plus immunotherapy for advanced lung cancer
This trial tests combining partial tumor radiation with immunotherapy for people with advanced lung adenocarcinoma who cannot have surgery or standard radiation. It may help those whose cancer has stopped responding to previous treatments.
Krems, AustriaAges 18 years+ - NCT06833632Recruiting
Studying cancer cells in the blood and air spaces for early lung cancer
This study looks for cancer cells that travel through the blood or spread through air spaces in the lungs of people with early-stage lung cancer. The goal is to understand how these cells affect the disease, and it may help doctors plan better treatment in the future.
Bologna, Emilia-RomagnaAges 18 years+ - NCT07359040Recruiting
Testing a new drug before surgery for lung cancer
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
Beijing, Beijing MunicipalityAges Any age - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT07325864Recruiting
Studying lung cancer and its spread to find new treatments
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
MilanAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Fountain Valley, CaliforniaAges 18 years+
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,010 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.